On September 20, 2023 Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, reported that four abstracts have been selected for presentation at the upcoming 2023 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), taking place October 11-15, 2023 in Boston, MA (Press release, Aadi Bioscience, SEP 20, 2023, View Source [SID1234635292]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations include four posters: a Trials-in-Progress (TiP) update from the PRECISION1 trial in TSC1/2 alterations, two real-world clinical genomic analyses, and one preclinical study of nab-sirolimus combinations in breast cancer xenograft models.

Poster Presentation Details:

Title: "Evaluation of nab-sirolimus in combination with PI3K pathway inhibitors to overcome PI3K/mTOR resistance in PI3K-mutant breast cancer cell lines"
Poster Number: A117
Session Title: Poster Session A
Date/Time: Thursday, October 12, 2023, 12:30 pm-4:00 pm
Authors: Sean Wallace, PhD, Khine Nyein Myint, PhD, Shihe Hou, PhD, Maria Zalath, BA, Andrew Kwon, PhD, Brian McMorran, PhD, Igor Vivanco, PhD

Title: "Phase 2, Multicenter, Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION1)"
Poster Number: LB_B12
Session Title: Poster Session B
Date/Time: Friday, October 13, 2023, 12:30 pm-4:00 pm
Authors: Candace Haddox, MD; Gopa Iyer, MD; Michael J. Demeure, MD; Li Ding, MS, MA; Anita N. Schmid, PhD; Willis H. Navarro, MD; David J. Kwiatkowski, MD, PhD; Jordi Rodon Ahnert, MD, PhD

Title: "Real-world (RW) characterization and frequency of TSC1 and/or TSC2 alterations collected from tumor tissue and liquid biopsies from the Tempus genomic database in patients with advanced cancer"
Poster Number: B003
Session Title: Poster Session B
Date/Time: Friday, October 13, 2023, 12:30 pm-4:00 pm
Authors: David J. Kwiatkowski, MD, PhD, Norma A. Palma, PhD, Willis H. Navarro, MD, Gopa Iyer, MD

Title: "Inactivating TSC1 and TSC2 alterations, co-mutations, and genomic instability in advanced cancers: Analysis of a real-world (RW) patient (pt) population using the Foundation Medicine genomic database"
Poster Number: C019
Session Title: Poster Session C
Date/Time: Saturday, October 14, 2023, 12:30 pm-4:00 pm
Authors: David J. Kwiatkowski, MD, PhD, Norma A. Palma, PhD, Willis H. Navarro, MD, Gopa Iyer, MD

More information can be found on the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) meeting website.